A Big Pharma CEO Is Battling Wall Street's Most Feared Fund.

Instead, the ugliest potential outcome would probably be a proxy fight, with Elliott asking investors to support a slate of new directors for GSK's board. Elliott doesn't have an issue with Walmsley emerging as the best candidate but wants the company, led by directors with pharmaceutical and science experience, to go through the process to prove it, according to people with knowledge of the matter. Keywords: AZN@LN; EBAY; GSK@LN; ME; MGGT@LN; MRK@GR; MRW@LN; ROG@SW; AI; ALLTOP; BASIC; BUSINESS; CMD; COS; DRG; EUROPE; EURTOP; GENTOP; HEA; INDUSTRIES; LAW; MARKETS; MED; METMNG; NORTHAM; STK; TEC; TMT; TOP; UK; US; WORLD; WWTOP; WWTOPAM; WWTOPAS; WWTOPEU EN AZN@LN EBAY GSK@LN ME MGGT@LN MRK@GR MRW@LN ROG@SW AI ALLTOP BASIC BUSINESS CMD COS DRG EUROPE EURTOP GENTOP HEA INDUSTRIES LAW MARKETS MED METMNG NORTHAM STK TEC TMT TOP UK US WORLD WWTOP WWTOPAM WWTOPAS WWTOPEU GSK's Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from. Many of the views Elliott heard from other GSK investors were the ones its executives expected: that the company wasn't producing enough big-hitting new drugs, or making bets bold enough to differentiate itself from other drugmakers. [Extracted from the article]